Delphi Management Partners VIII
Latest statistics and disclosures from Delphi Management Partners VIII's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TNDM, Karyopharm Therapeutics, Calithera Biosciences, MREO, and represent 100.00% of Delphi Management Partners VIII's stock portfolio.
- Delphi Management Partners VIII has $139M in assets under management (AUM), dropping by 9.33%.
- Central Index Key (CIK): 0001457494
Tip: Access up to 7 years of quarterly data
Positions held by Delphi Management Partners VIII consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Delphi Management Partners VIII
Delphi Management Partners VIII holds 4 positions in its portfolio as reported in the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Tandem Diabetes Common Stock (TNDM) | 86.2 | $119M | 1.0M | 119.38 |
|
|
| Karyopharm Therapeutics Common Stock | 9.5 | $13M | 2.3M | 5.82 |
|
|
| Calithera Biosciences Common Stock | 3.8 | $5.3M | 2.4M | 2.18 |
|
|
| Mereo BioPharma Group Ads (MREO) | 0.4 | $621k | 257k | 2.42 |
|
Past Filings by Delphi Management Partners VIII
SEC 13F filings are viewable for Delphi Management Partners VIII going back to 2019
- Delphi Management Partners VIII 2021 Q3 filed Nov. 15, 2021
- Delphi Management Partners VIII 2021 Q2 filed Aug. 12, 2021
- Delphi Management Partners VIII 2021 Q1 filed May 17, 2021
- Delphi Management Partners VIII 2020 Q4 filed Feb. 8, 2021
- Delphi Management Partners VIII 2019 Q4 filed Feb. 7, 2020